Due Diligence Capital Notes

Most companies write a check when they want to buy something. AST SpaceMobile wrote its own stock. On September 25, 2025, ASTS completed its acquisition of EllioSat Ltd. from a holding company called CCUR Holdings — and instead of wiring $26 million in cash, it handed over 581,395 newly created Class A shares. The very next day, those shares were registered for open-market resale by the seller.

That sequence of events — acquire a company, dilute your shareholders, immediately allow the seller to dump the shares into the public market — sounds alarming on the surface. But once you unpack the financial mechanics, it reveals something more nuanced: a deliberate choice to preserve cash for satellite launches while using a richly priced stock as acquisition currency. Whether that trade-off is good for long-term ASTS holders depends on a few things I want to walk through carefully.

Stock-as-Currency: How Companies Pay with Shares Instead of Cash

Before dissecting this specific deal, it helps to understand the basic mechanism. When a company makes an all-stock acquisition, it issues new shares to the seller rather than spending cash. The seller receives equity in the acquirer, and the acquirer conserves its cash balance. The economics only work well if the acquirer's stock is priced generously relative to the assets being purchased — because you want to acquire a $26 million asset by issuing as few shares as possible.

The implied price per share in this transaction was approximately $44.72 (derived simply: $26,000,000 ÷ 581,395 shares). That is the valuation ASTS's stock carried at the time the consideration was set. For a company building a global broadband satellite network that has burned substantial cash on infrastructure, holding onto $26 million of hard cash — rather than spending it — has real strategic value. Every dollar not spent on an acquisition is potentially one more satellite component, one more ground station, one more quarter of operational runway.

The flip side is equally straightforward. Issuing 581,395 new Class A shares means existing shareholders now own a fractionally smaller piece of the same company. If ASTS's total share count was, say, 250 million before this transaction, adding ~581,000 shares represents roughly 0.23% additional dilution from this payment alone. That figure sounds small — and from a single tranche, it is. But the 8-K filed September 26, 2025 explicitly describes this as the "first required consideration payment," which tells us there are more tranches coming. The total deal size, payment schedule, and whether future installments will be cash or stock have not been disclosed in this filing.

How This Deal Was Actually Structured

Let me break down the moving parts of the EllioSat transaction specifically, because several distinct mechanisms are layered on top of one another.

The Share Purchase Agreement. ASTS and CCUR Holdings first signed an agreement on August 5, 2025, with the deal subject to amendment before closing. The acquisition closed nearly seven weeks later, on September 25, 2025. The gap between signing and closing is standard — it allows for regulatory review, due diligence confirmation, and documentation. That the agreement required amendment suggests the parties renegotiated at least some terms between signing and closing.
The private placement exemption. When ASTS issued the 581,395 Class A shares to CCUR, it relied on Section 4(a)(2) of the Securities Act — an exemption that allows companies to issue securities in private transactions without first registering them with the SEC. The exemption applies when the offering is not made to the general public, i.e., you are selling directly to a single sophisticated counterparty. CCUR Holdings fits that description. The catch: shares issued under Section 4(a)(2) are "restricted securities," meaning the holder cannot freely resell them into the public market right away — unless the company registers those shares for resale.
The S-3 shelf and prospectus supplement. On the same day as closing, ASTS filed a prospectus supplement under its existing S-3 shelf registration (Registration No. 333-281939). An S-3 shelf is a pre-approved registration statement that lets a company register large blocks of securities in advance and then access them quickly when needed — think of it as a loaded magazine rather than having to reload from scratch every time. A prospectus supplement is the specific document filed under that shelf to register a particular tranche. By filing this supplement on September 26, 2025, ASTS effectively unlocked CCUR's ability to sell those 581,395 shares into the public market immediately. As the Form 8-K filed with the SEC states directly: "the Company filed a prospectus supplement…to register the offer and resale of the Consideration Shares."
What ASTS actually acquired. The filing confirms that ASTS now owns 100% of the issued and outstanding equity interests in EllioSat Ltd. EllioSat is described as a technology company, though the 8-K does not disclose its revenue, assets, liabilities, or a detailed description of its intellectual property. That opacity is worth noting. Investors are being asked to accept dilution for a technology asset whose financial profile is not publicly quantified in this document.
The installment structure. Perhaps the most important sentence in the entire 8-K is the description of this $26 million payment as the first required consideration payment. That word "first" tells us the total acquisition price exceeds $26 million by an undisclosed amount. Future installments could be paid in stock, in cash, or in some combination. Each stock-based tranche would repeat this entire cycle: new shares issued, registered, and made available for immediate resale by the recipient.

The Numbers in Context

The Form 8-K filed on September 26, 2025 contains the following direct quote from Item 8.01:

"the Company elected to pay its first required consideration payment of $26.0 million to CCUR Holdings, Inc. in the form of 581,395 shares of the Company's Class A common stock"

The word "elected" is doing meaningful work there. ASTS chose to pay in stock. This was not a forced mechanism — the company had the option and deliberately selected equity over cash. That choice tells me something about how management views the relative cost of capital at that moment. If management believed the stock was deeply undervalued, issuing shares to pay for an acquisition would be expensive (you'd be giving away undervalued equity). If management believed the stock was fairly or richly valued, issuing shares is the rational choice — you are effectively spending "expensive" paper to preserve scarce cash.

At ~$44.72 per implied share price and given where ASTS was trading during Q3 2025, this calculation reflects management's view that the stock price offered efficient acquisition currency. Whether you agree depends on your own view of ASTS's intrinsic value.

The resale registration happening on the same calendar day as closing is also worth sitting with. CCUR Holdings is not a strategic long-term holder of ASTS equity. It is a holding company that sold a subsidiary and received shares it presumably intends to monetize. The immediate S-3 registration signals exactly that. This creates what traders call a resale overhang — the knowledge that a meaningful block of shares is available for sale, which can create downward pressure on the stock price as market participants price in the expected supply.

581,395 shares is not a catastrophically large block in isolation. But combined with the uncertainty about future tranches, investors should watch how CCUR's disclosed selling activity (reported via Form 144 or Schedule 13G/D filings) unfolds over subsequent weeks and quarters.

What Could Break This Thesis

Any honest look at this transaction requires naming the specific scenarios that make it a poor outcome for long-term ASTS shareholders.

Cumulative dilution from future tranches. This filing only covers the first installment. If the remaining consideration is large and paid predominantly in stock at a lower implied price per share than the first tranche, the dilutive math compounds. Without knowing the full deal structure, investors cannot model the total share count impact. That is a genuine blind spot.
Resale pressure from CCUR Holdings. CCUR received 581,395 freely tradeable shares the moment the prospectus supplement was filed. There is nothing preventing CCUR from selling its entire position quickly. If it does, concentrated selling into what may be a thin float creates downward price pressure that affects all ASTS shareholders — including long-term believers who have nothing to do with this transaction.
EllioSat's technology may not be material to ASTS's mission. The 8-K provides no financial statements, no description of EllioSat's customer base, revenue model, or how its technology integrates with ASTS's BlueBird satellite constellation. If EllioSat turns out to be a small, subscale technology tuck-in with no meaningful contribution to ASTS's broadband coverage or spectrum position, then management spent acquisition currency — however non-cash — without moving the needle on the core business.
Execution risk on the satellite network remains the dominant variable. EllioSat is a footnote compared to the central challenge ASTS faces: deploying enough BlueBird satellites to deliver commercially viable broadband directly to smartphones at scale. No corporate development activity — however cleverly structured — changes that fundamental execution dependency. If the satellite program slips on costs, launch schedules, or regulatory approvals, no technology acquisition rescues the investment thesis.

Conclusion

The EllioSat acquisition is a small transaction in the context of ASTS's overall capital structure and mission, but it is a useful window into how management thinks about capital allocation. The decision to pay in stock rather than cash is a deliberate preservation of liquidity at a moment when ASTS needs every dollar for its satellite infrastructure buildout. The use of a Section 4(a)(2) private placement followed immediately by an S-3 prospectus supplement is textbook execution — legally clean, operationally fast, and structurally sensible.

What I will be watching is the cumulative picture that emerges as subsequent consideration tranches are disclosed. The full deal economics — total acquisition price, payment schedule, and how much of EllioSat's technology is genuinely differentiated — are not visible from this single 8-K. For now, the transaction is accretive to ASTS's technology portfolio in theory, marginally dilutive to existing shareholders in practice, and incomplete in disclosure. As a long-term holder, I am not alarmed by 581,000 new shares. I am curious about what comes next on the installment schedule — and whether EllioSat's intellectual property eventually shows up in ASTS's product capabilities in a way that justifies the total consideration paid.